Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 12, 2022

View Archived Issues

CD22 aberrant splicing confers resistance to therapy in B-ALL

Dysregulation of the tRNA synthetase modulator NOTCH1 behind T-ALL pathogenesis

Discovery of novel hybrid compounds as antitubercular agents

TuA-derived hPep elicits long-term anticancer immunity in mice

Leo Pharma discloses IL-17 modulators

Amgen and Arrakis collaborate to discover and develop targeted RNA degrader therapeutics

Anaxis Pharma patents MLKL inhibitors

Abbisko Therapeutics identifies new PD-1/PD-L1 interaction inhibitors

Betta Pharmaceuticals synthesizes new HIF-2alpha inhibitors

Wigen Biomedicine Technology presents new CDK inhibitors

CD6-ALCAM pathway is a therapeutic target in SLE

Methamphetamine harnessed for good in BBB transport

REVTx-99 demonstrates in vitro antiviral activity against SARS-CoV-2

PostEra and Pfizer expand strategic collaboration

VCAM-1-targeting polyelectrolyte complex enhances therapeutic efficacy of miR-92a inhibitors in vivo

Dren Bio and Pfizer collaborate to discover and develop bispecific antibodies for cancer

ABL and Sanofi enter collaboration and license agreement for ABL-301

G3PP is a therapeutic target for age-related metabolic diseases

Neogene licenses portfolio of TCRs targeting KRAS and TP53 mutations from NCI

A simple method for the synthesis of isoxazole derivatives with in vitro antitumor activity

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis
BioWorld
Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
Sanofi phase III CIDP quit dents Dianthus; C1 mismatch?
BioWorld
Investors in Dianthus Therapeutics Inc. apparently chose to ignore subtleties in the difference between efforts with that firm’s claseprubart vs. those by...
Jiangsu Nhwa Pharmaceutical patents new κ-opioid receptor antagonists
BioWorld Science
Jiangsu Nhwa Pharmaceutical Co. Ltd. has disclosed κ-opioid receptor antagonists that are potentially useful for the treatment of neurological disorders.